Signal
Novartis acquires Synnovation’s PI3Kα breast cancer drug in multi-billion dollar deal
Novartis has acquired a unit of privately held Synnovation Therapeutics for up to $3 billion, securing a promising PI3Kα inhibitor aimed at treating breast cancers driven by PIK3CA mutations.
redditrss
clinical_trialsdrug_developmentbiotech_funding
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- BioPharma Dive (via Reddit)biopharmadive.com
- Novartis snaps up PI3Kα breast cancer drug in $3bn dealpharmaphorum